2024-11-15 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**1. Performance Comparison:**

Abbott Laboratories (ABT) is a healthcare company that develops, manufactures, and sells a wide range of healthcare products, including pharmaceuticals, medical devices, nutritionals, and diagnostics.

**Performance Summary:**

* **Cumulative Return:** 141.89%
* **S&P 500 (VOO) Cumulative Return:** 179.47%
* **Performance Gap:** -37.58% (vs. S&P 500)
* **Relative Outperformance Rank:** 9.0% (meaning ABT has outperformed the S&P 500 for 90% of the time period considered).

**Alpha & Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 36.2% | 23.4% | -2.2% | 1.1 | 99.0 |
| 2016-2018  | 80.0% | 14.7% | 47.7% | 1.1 | 125.5 |
| 2017-2019  | 135.6% | 11.7% | 83.9% | 1.1 | 150.7 |
| 2018-2020  | 95.8% | 31.2% | 48.5% | 0.9 | 189.9 |
| 2019-2021  | 112.3% | 31.2% | 12.3% | 0.8 | 244.1 |
| 2020-2022  | 32.4% | 31.2% | 8.8% | 0.8 | 190.4 |
| 2021-2023  | 6.2% | 30.6% | -28.7% | 0.7 | 190.9 |
| 2022-2024  | -11.9% | 29.6% | -42.4% | 0.7 | 202.0 |

* **Alpha:**  The alpha value indicates ABT's ability to outperform the market (S&P 500) after accounting for its beta. A positive alpha signifies that ABT has generated higher returns than expected based on its market risk. 
* **Beta:** The beta value measures the volatility of ABT's stock price compared to the market. A beta of 1 means the stock's price will move in line with the market. A beta greater than 1 indicates higher volatility, while a beta less than 1 indicates lower volatility.

**2. Recent Price Movement:**

* **Closing Price:** $115.74 (Last-market: $115.81)
* **5-day Moving Average:** $116.17
* **20-day Moving Average:** $116.26
* **60-day Moving Average:** $114.71

**3. Technical Indicators:**

* **RSI:** 47.58 (Neutral)
* **PPO:** -0.08 (Slightly bearish)
* **Recent (20-day) Relative Divergence:** -7.98 (Short-term bearish)
* **Expected Return:** 0.0% (Long-term, 2+ years, expected to match S&P 500 returns).

**4. Recent Earnings and Outlook:**

| Date       | EPS | Revenue |
|------------|-----|---------|
| 2024-10-31 | 0.94 | $10.63 B |
| 2024-07-31 | 0.74 | $10.38 B |
| 2024-05-02 | 0.7 | $9.96 B |
| 2023-11-01 | 0.82 | $10.14 B |
| 2024-10-31 | 0.82 | $10.14 B |

* **Most Recent Earnings:** The most recent earnings report (October 31, 2024) showed EPS of $0.94, beating analyst expectations by a significant margin. The company also reported strong revenue growth.
* **Outlook:**  Analysts are generally optimistic about ABT's future prospects, expecting continued growth driven by its diversified product portfolio and robust R&D pipeline.

**5. Financial Data:**

**Revenue and Profitability:**

| Quarter  | Revenue  | Profit Margin |
|---|---|---|
| 2024-09-30 | $10.63B | 55.83% |
| 2024-06-30 | $10.38B | 55.64% |
| 2024-03-31 | $9.96B | 55.21% |
| 2023-12-31 | $10.24B | 55.51% |
| 2023-09-30 | $10.14B | 54.60% |

**Capital and Profitability:**

| Quarter  | Equity  | ROE |
|---|---|---|
| 2024-09-30 | $39.80B | 4.14% |
| 2024-06-30 | $39.32B | 3.31% |
| 2024-03-31 | $38.81B | 3.16% |
| 2023-12-31 | $38.60B | 4.13% |
| 2023-09-30 | $37.48B | 3.83% |

* **Strong Profitability:** ABT consistently demonstrates strong profitability with high profit margins and healthy ROE. 
* **Stable Revenue Growth:** The company exhibits steady and consistent revenue growth, indicating a stable and expanding business.

**6. News & Recent Issues:**

* **Earnings Release:**  ABT's recent earnings release on October 31, 2024, was met with positive reactions from analysts and investors due to the strong performance exceeding expectations.
* **Market Outlook:** Analyst opinions on ABT remain positive, citing its strong fundamentals, diverse product portfolio, and growth potential in the healthcare sector. 
* **Recent Headlines:**  A quick search on FINBOLD reveals recent news about ABT including updates on their FDA approvals for new medical devices, continued growth in the diagnostics segment, and expansion into emerging markets. 

**7. Overall Analysis:**

ABT's performance is generally in line with the market, demonstrating consistent growth and strong financial fundamentals. Despite a slight underperformance compared to the S&P 500, the company's high profit margins, stable revenue growth, and positive analyst outlook indicate a strong future outlook. 

**For long-term investors (2+ years), ABT offers a solid investment opportunity with a reasonable expected return potential in line with the S&P 500.** 

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Always consult with a qualified financial advisor before making any investment decisions. 
